Life Science Investing Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Life Science Investing Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition
Life Science Investing Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
Life Science Investing Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference
